Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Austria-based Nabriva Therapeutics, which is engaged in the discovery and development of antibacterial agents, has appointed George Golumbeski as CEO of the company.
Subscribe to our email newsletter
Dr Golumbeski brings to the team nearly 20 years of industry experience serving most recently as vice president of business development, licensing and strategy for the oncology business unit at Novartis.
In this position he was responsible for the full array of business development activities leading several transactions which have resulted in projects currently in Phase III studies.
David Chiswell, chair of the supervisory board at Nabriva, said: “We are pleased to welcome George to the team. His leadership skills combined with his strategic and business development insight will help position Nabriva as one of the leading specialist companies in antibiotics development.”